Cel-Sci Corp (CVM)

$6.62 -0.01 (-0.15%)
Market Cap 53.15M
Revenue (ttm) 0.00
Net Income (ttm) -26.92M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 55,400
Avg Vol 112,102
Day's Range N/A - N/A
Shares Out 8.02M
Stochastic %K 13%
Beta 0.49
Analysts Strong Sell
Price Target $180.18

Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune syste...

Industry: Biotechnology
Sector: Healthcare
Phone: 703 506 9460
Website: cel-sci.com
Address:
8229 Boone Boulevard, Suite 802, Vienna, United States
ImmxBeliever
ImmxBeliever Nov. 14 at 9:24 PM
$CVM More 13Fs posted just now Not looking good Cheers
0 · Reply
ImmxBeliever
ImmxBeliever Nov. 14 at 6:58 PM
$CVM Hi. Immx just made another new 52 week high Cheers
0 · Reply
Easygoer712
Easygoer712 Nov. 14 at 6:44 PM
$AVXL $CVM take your losses here and get into Cel Sci. They will have approval with the SFDA by the end of the year. Book it. And are starting their confirmatory trial for their Phase 3 with the FDA next month. A really easy way to get back your losses quickly. Thank you for your attention to this matter.
2 · Reply
ThaDreadPirate
ThaDreadPirate Nov. 14 at 6:35 PM
Openly inviting all $AVXL bulls who lost the shirt off their back this morning to buy into $CVM who also has a CEO convincing investors they are going to get approval (in Saudi Arabia) for their only drug, Multikine that FAILED ALL ENDPOINTS in the phase 3 trial. I would like to short shares at a higher price, please and thank you.
1 · Reply
BioGLovesMe
BioGLovesMe Nov. 14 at 4:47 PM
$CVM AVXL fails to get a positive CHMP opinion on their moonshot alzheimers drug. Yet another into the dustbin of junk bio history. I have bern bearish on this one for awhile as well. Looking forward to being proven right on CVM in due time.
2 · Reply
CashNCarry
CashNCarry Nov. 14 at 4:36 PM
$CVM SOON!!!!!!!
0 · Reply
Cruiser24
Cruiser24 Nov. 14 at 3:54 PM
$CVM BULLISH @Cruiser24 💎✋🤚💎 Happy Friday GLTA-BULLS POAY-bears
1 · Reply
ImmxBeliever
ImmxBeliever Nov. 14 at 3:42 PM
$CVM I love winning Cheers
0 · Reply
ImmxBeliever
ImmxBeliever Nov. 14 at 3:41 PM
$CVM IMMX says what?!
0 · Reply
drkazmd65
drkazmd65 Nov. 14 at 3:30 PM
$CVM - Yet another day with almost no volume traded. Everybody is just waiting for something to react to.
1 · Reply
Latest News on CVM
CEL-SCI Presentation at LD Micro "Main Event" Available on Tuesday, October 21, 2025

Oct 20, 2025, 9:00 AM EDT - 25 days ago

CEL-SCI Presentation at LD Micro "Main Event" Available on Tuesday, October 21, 2025

CEL-SCI Corporation to Present at LD Micro "Main Event" Investor Conference

Oct 10, 2025, 8:00 AM EDT - 5 weeks ago

CEL-SCI Corporation to Present at LD Micro "Main Event" Investor Conference

CEL-SCI Announces Closing of $10 Million Public Offering

Aug 29, 2025, 12:52 PM EDT - 2 months ago

CEL-SCI Announces Closing of $10 Million Public Offering

CEL-SCI Announces Pricing of $10 Million Public Offering

Aug 27, 2025, 10:35 PM EDT - 2 months ago

CEL-SCI Announces Pricing of $10 Million Public Offering

CEL-SCI Announces Proposed Public Offering

Aug 27, 2025, 5:25 PM EDT - 2 months ago

CEL-SCI Announces Proposed Public Offering

CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results

Aug 14, 2025, 10:45 AM EDT - 3 months ago

CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results

CEL-SCI's Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline

Aug 13, 2025, 9:15 AM EDT - 3 months ago

CEL-SCI's Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline

CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules

Jul 14, 2025, 4:05 PM EDT - 4 months ago

CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules

CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules

Jul 11, 2025, 12:16 PM EDT - 4 months ago

CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules

CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer

Jul 11, 2025, 9:15 AM EDT - 4 months ago

CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer

FDA's Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI's Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients

Jun 18, 2025, 9:00 AM EDT - 5 months ago

FDA's Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCI's Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients

CEL-SCI Announces Closing of Public Offering

May 23, 2025, 4:05 PM EDT - 6 months ago

CEL-SCI Announces Closing of Public Offering

CEL-SCI Announces Pricing of Public Offering

May 21, 2025, 8:14 PM EDT - 6 months ago

CEL-SCI Announces Pricing of Public Offering

CEL-SCI's Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia

May 21, 2025, 8:00 AM EDT - 6 months ago

CEL-SCI's Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia

CEL-SCI Announces Combination of Common Stock

May 19, 2025, 2:40 PM EDT - 6 months ago

CEL-SCI Announces Combination of Common Stock

CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results

May 15, 2025, 9:00 AM EDT - 6 months ago

CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results

CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market

Apr 23, 2025, 8:30 AM EDT - 7 months ago

CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market

New Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI's Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses

Apr 8, 2025, 9:51 AM EDT - 7 months ago

New Study in the Scientific Journal “Cancer Cell” Supports CEL-SCI's Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses

CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients

Mar 24, 2025, 9:00 AM EDT - 8 months ago

CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients

CEL-SCI Announces Closing of $2.5 Million Offering

Mar 18, 2025, 4:05 PM EDT - 8 months ago

CEL-SCI Announces Closing of $2.5 Million Offering

CEL-SCI Announces Pricing of $2.5 Million Offering

Mar 17, 2025, 3:24 PM EDT - 8 months ago

CEL-SCI Announces Pricing of $2.5 Million Offering

CEL-SCI's Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine

Mar 17, 2025, 8:00 AM EDT - 8 months ago

CEL-SCI's Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine

Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI's Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression

Mar 14, 2025, 8:30 AM EDT - 8 months ago

Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI's Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression

CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial

Feb 20, 2025, 8:00 AM EST - 9 months ago

CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial

CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks

Feb 18, 2025, 8:30 AM EST - 9 months ago

CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks

CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer

Jan 14, 2025, 9:00 AM EST - 10 months ago

CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer

CEL-SCI Announces Closing of $5 Million Offering

Dec 31, 2024, 4:05 PM EST - 11 months ago

CEL-SCI Announces Closing of $5 Million Offering

CEL-SCI Announces Pricing of $5 Million Public Offering

Dec 29, 2024, 8:41 PM EST - 11 months ago

CEL-SCI Announces Pricing of $5 Million Public Offering

CEL-SCI Announces Proposed Public Offering of Common Stock

Dec 27, 2024, 5:05 PM EST - 11 months ago

CEL-SCI Announces Proposed Public Offering of Common Stock

CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study

Dec 12, 2024, 9:15 AM EST - 1 year ago

CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study

Stock Picks From Seeking Alpha's October 2024 New Analysts

Nov 8, 2024, 8:00 AM EST - 1 year ago

Stock Picks From Seeking Alpha's October 2024 New Analysts

ACGL AMCX AMPS APOG AVRE BHP BILL

U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025

Nov 7, 2024, 8:15 AM EST - 1 year ago

U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025

FDA's Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI's Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients

Oct 22, 2024, 9:15 AM EDT - 1 year ago

FDA's Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI's Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients

CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer

Oct 1, 2024, 6:00 AM EDT - 1 year ago

CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer

CEL-SCI's Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation

Sep 16, 2024, 7:30 AM EDT - 1 year ago

CEL-SCI's Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation

CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress

Sep 10, 2024, 9:32 AM EDT - 1 year ago

CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress

The UK's Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance

Sep 4, 2024, 9:00 AM EDT - 1 year ago

The UK's Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance

CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results

Aug 15, 2024, 8:00 AM EDT - 1 year ago

CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results

CEL-SCI Announces Closing of $10.8 Million Offering

Jul 29, 2024, 4:05 PM EDT - 1 year ago

CEL-SCI Announces Closing of $10.8 Million Offering

CEL-SCI Announces Pricing of $10.8 Million Offering

Jul 26, 2024, 11:52 AM EDT - 1 year ago

CEL-SCI Announces Pricing of $10.8 Million Offering

CEL-SCI's Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results

Jul 26, 2024, 8:23 AM EDT - 1 year ago

CEL-SCI's Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results

CEL-SCI Appoints Robert Watson as Chairperson of the Board

Jul 8, 2024, 9:15 AM EDT - 1 year ago

CEL-SCI Appoints Robert Watson as Chairperson of the Board

CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population

Jun 18, 2024, 8:00 AM EDT - 1 year ago

CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population

Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

Jun 6, 2024, 7:00 AM EDT - 1 year ago

Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results

May 16, 2024, 9:00 AM EDT - 1 year ago

CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results

CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer

May 8, 2024, 9:00 AM EDT - 1 year ago

CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer

CEL-SCI Appoints Mario Gobbo to Its Board of Directors

Apr 23, 2024, 9:00 AM EDT - 1 year ago

CEL-SCI Appoints Mario Gobbo to Its Board of Directors

Channel V Media Expands Content Marketing Division; Names Gabriella Bock Director of Content

Apr 16, 2024, 9:00 AM EDT - 1 year ago

Channel V Media Expands Content Marketing Division; Names Gabriella Bock Director of Content

CEL-SCI's LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology

Mar 19, 2024, 9:00 AM EDT - 1 year ago

CEL-SCI's LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology

CEL-SCI Corporation Issues Letter to Shareholders

Mar 6, 2024, 8:45 AM EST - 1 year ago

CEL-SCI Corporation Issues Letter to Shareholders

ImmxBeliever
ImmxBeliever Nov. 14 at 9:24 PM
$CVM More 13Fs posted just now Not looking good Cheers
0 · Reply
ImmxBeliever
ImmxBeliever Nov. 14 at 6:58 PM
$CVM Hi. Immx just made another new 52 week high Cheers
0 · Reply
Easygoer712
Easygoer712 Nov. 14 at 6:44 PM
$AVXL $CVM take your losses here and get into Cel Sci. They will have approval with the SFDA by the end of the year. Book it. And are starting their confirmatory trial for their Phase 3 with the FDA next month. A really easy way to get back your losses quickly. Thank you for your attention to this matter.
2 · Reply
ThaDreadPirate
ThaDreadPirate Nov. 14 at 6:35 PM
Openly inviting all $AVXL bulls who lost the shirt off their back this morning to buy into $CVM who also has a CEO convincing investors they are going to get approval (in Saudi Arabia) for their only drug, Multikine that FAILED ALL ENDPOINTS in the phase 3 trial. I would like to short shares at a higher price, please and thank you.
1 · Reply
BioGLovesMe
BioGLovesMe Nov. 14 at 4:47 PM
$CVM AVXL fails to get a positive CHMP opinion on their moonshot alzheimers drug. Yet another into the dustbin of junk bio history. I have bern bearish on this one for awhile as well. Looking forward to being proven right on CVM in due time.
2 · Reply
CashNCarry
CashNCarry Nov. 14 at 4:36 PM
$CVM SOON!!!!!!!
0 · Reply
Cruiser24
Cruiser24 Nov. 14 at 3:54 PM
$CVM BULLISH @Cruiser24 💎✋🤚💎 Happy Friday GLTA-BULLS POAY-bears
1 · Reply
ImmxBeliever
ImmxBeliever Nov. 14 at 3:42 PM
$CVM I love winning Cheers
0 · Reply
ImmxBeliever
ImmxBeliever Nov. 14 at 3:41 PM
$CVM IMMX says what?!
0 · Reply
drkazmd65
drkazmd65 Nov. 14 at 3:30 PM
$CVM - Yet another day with almost no volume traded. Everybody is just waiting for something to react to.
1 · Reply
ImmxBeliever
ImmxBeliever Nov. 14 at 3:24 PM
$CVM LEAK!
0 · Reply
Ichigodoran
Ichigodoran Nov. 14 at 2:00 PM
$CVM “CEL-SCI has a dedicated and passionate team that believes boosting a patient’s immune system while it is still intact should provide the greatest possible impact on survival when it comes to cancer immunotherapy.” https://cel-sci.com/about-us/
0 · Reply
Cruiser24
Cruiser24 Nov. 14 at 7:11 AM
$CVM
0 · Reply
ImmxBeliever
ImmxBeliever Nov. 13 at 11:05 PM
$CVM I have learned that tomorrow is the day. There will be an announcement that the SFDA denied and Cvm is starting the confirmatory trial in Q2 2026 Geert will first raise $14M and it will crush the stock. That gets him thru summer 26 I love being right IMMX is releasing more data Dec 7 as part of their oral presentation. Yes oral. Not normal for a company this size to be invited to present an oral presentation Cheers
2 · Reply
andreg_26
andreg_26 Nov. 13 at 11:04 PM
$CVM have to agree, will be watching, but can’t keep track of this board. Good luck everyone‼️🗣️
0 · Reply
ImmxBeliever
ImmxBeliever Nov. 13 at 10:49 PM
$CVM Tell me you’re a moron without telling me you’re a moron. This guy invests in both CVM and NWBO 🤡🤡🤡 Cheers 
1 · Reply
Bjfrank87
Bjfrank87 Nov. 13 at 9:36 PM
$CVM there are a bunch of kooks on both sides of the ball here. This message board has gone to crap. I think I’ll take a break until something happens here. GLTA
1 · Reply
Cruiser24
Cruiser24 Nov. 13 at 9:26 PM
$CVM BULLISH @cruiser24 💎✋🤚💎 Who are you trying to kidd? Everyone knows you can’t tell time. If you could youbwoukd have shut up a long time ago. GLTA-BULLS. POAY/bears 💎✋🤚💎. 💎✋🤚💎
0 · Reply
Johnyd
Johnyd Nov. 13 at 9:19 PM
$CVM also, DALLAH IS a tax shelter.
0 · Reply
Johnyd
Johnyd Nov. 13 at 9:18 PM
$CVM won't be another trial ANYWHERE. It is a placebo. They either have another shareoffer or they close up!
0 · Reply
Johnyd
Johnyd Nov. 13 at 9:13 PM
$CVM No physical record record of any application to SAFDA by anyone. no news on a corp or gov website. bart beerstein carsteen is a crook!
0 · Reply
DeepThought
DeepThought Nov. 13 at 8:50 PM
$CVM The first time CVM mentioned a Saudi partner was on a Friday… and surprisingly, the SFDA isn't even required to make the classification public before informing the company. This could have happened the day before yesterday, or yesterday. Patents? Really. One should take a closer look at Orphan Drug Status or the SFDA’s Breakthrough Medicine Designation. It’s called non-patent exclusivity. BananaMonkeyClown just uttered the word “biostatistics.” That’s hilarious… Nice dreams!
0 · Reply